Pandemic Influenza and the Global Vaccine Supply
Identifieur interne : 001711 ( Main/Exploration ); précédent : 001710; suivant : 001712Pandemic Influenza and the Global Vaccine Supply
Auteurs : David S. Fedson [France]Source :
- Clinical Infectious Diseases [ 1058-4838 ] ; 2003.
Abstract
Use of influenza vaccine is increasing, especially in developing countries. Yet most of the world's influenza vaccine is produced by companies located in 9 developed countries. When the threat of an influenza pandemic appears, the traditional approach to providing interpandemic vaccines will not be able to meet the global demand for pandemic vaccine. Several steps must be taken to address this problem, including the use of reverse genetics to prepare seed strains for vaccine production, the undertaking of clinical studies to define the characteristics of candidate “pandemic-like” vaccines and vaccination schedules, the development of procedures for global vaccine registration, the expansion of recommendations and reimbursement for interpandemic vaccination, the country-specific reporting of vaccine use and forecasts of future vaccine needs, and the negotiation of political agreements that will ensure the adequate production and equitable distribution of pandemic vaccine throughout the world.
Url:
DOI: 10.1086/375056
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001708
- to stream Istex, to step Curation: 001708
- to stream Istex, to step Checkpoint: 000577
- to stream Main, to step Merge: 001747
- to stream Main, to step Curation: 001711
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Pandemic Influenza and the Global Vaccine Supply</title><author wicri:is="90%"><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S." last="Fedson">David S. Fedson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C4255C8822263AB053EF87AF87AD96E848E1117</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1086/375056</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-5LX4Z13G-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001708</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001708</idno><idno type="wicri:Area/Istex/Curation">001708</idno><idno type="wicri:Area/Istex/Checkpoint">000577</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000577</idno><idno type="wicri:doubleKey">1058-4838:2003:Fedson D:pandemic:influenza:and</idno><idno type="wicri:Area/Main/Merge">001747</idno><idno type="wicri:Area/Main/Curation">001711</idno><idno type="wicri:Area/Main/Exploration">001711</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pandemic Influenza and the Global Vaccine Supply</title><author wicri:is="90%"><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S." last="Fedson">David S. Fedson</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Sergy Haut</wicri:regionArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical Infectious Diseases</title><title level="j" type="abbrev">Clinical Infectious Diseases</title><idno type="ISSN">1058-4838</idno><idno type="eISSN">1537-6591</idno><imprint><publisher>The University of Chicago Press</publisher><date when="2003-06-15">2003</date><biblScope unit="vol">36</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1552">1552</biblScope><biblScope unit="page" to="1561">1561</biblScope></imprint><idno type="ISSN">1058-4838</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1058-4838</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Use of influenza vaccine is increasing, especially in developing countries. Yet most of the world's influenza vaccine is produced by companies located in 9 developed countries. When the threat of an influenza pandemic appears, the traditional approach to providing interpandemic vaccines will not be able to meet the global demand for pandemic vaccine. Several steps must be taken to address this problem, including the use of reverse genetics to prepare seed strains for vaccine production, the undertaking of clinical studies to define the characteristics of candidate “pandemic-like” vaccines and vaccination schedules, the development of procedures for global vaccine registration, the expansion of recommendations and reimbursement for interpandemic vaccination, the country-specific reporting of vaccine use and forecasts of future vaccine needs, and the negotiation of political agreements that will ensure the adequate production and equitable distribution of pandemic vaccine throughout the world.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S." last="Fedson">David S. Fedson</name></noRegion><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S." last="Fedson">David S. Fedson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001711 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001711 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9C4255C8822263AB053EF87AF87AD96E848E1117
|texte= Pandemic Influenza and the Global Vaccine Supply
}}
| This area was generated with Dilib version V0.6.33. |  |